Related references
Note: Only part of the references are listed.Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
Anthony Traboulsee et al.
LANCET NEUROLOGY (2020)
Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials
Tao Xue et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
Takashi Yamamura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options
Nicolas Collongues et al.
DRUGS (2019)
Association of Visual Impairment in Neuromyelitis Optica Spectrum Disorder With Visual Network Reorganization
Carsten Finke et al.
JAMA NEUROLOGY (2018)
Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic
Remi A. Kessler et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2016)
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies
Marios C. Papadopoulos et al.
NATURE REVIEWS NEUROLOGY (2014)
Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica
Norio Chihara et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
IL-6: Regulator of Treg/Th17 balance
Akihiro Kimura et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
Tomoyuki Igawa et al.
NATURE BIOTECHNOLOGY (2010)
Share Paper
